Telo Genomics Corp. (TSXV: TELO)
Health Care · Biotechnology · CA
CA$0.06
-14.29% today · -14.3% 1Y
Telo Genomics Corp. (TSXV: TELO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.26M and employs 8 people.
Over the last twelve months the share price has lost 14.3%, trading between 0.03 and 0.11.
Tweenvest scores Telo Genomics Corp. across four factors: quality 26/100, value 34/100. Its strongest factor is value.
TELO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.26M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.11
- 52-week high
- CA$0.11
- 52-week low
- CA$0.03
- Avg volume (3M)
- —
- Shares outstanding
- 100.43M
- Employees
- 8
- Next earnings
- —
About Telo Genomics Corp.
Telo Genomics Corp. (TELO.V) operates as a biotechnology firm focused on creating and bringing to market advanced predictive solutions. Its core mission is to enable personalized treatment approaches for individuals suffering from specific health conditions. The company's primary innovation is a sophisticated telomere analysis platform, which serves both to diagnose diseases and to forecast patient outcomes. This technology, often integrated with liquid biopsies, provides crucial insights for applications in both cancer and neurological illnesses. Their leading product, Telo-MM, is specifically designed to arm medical professionals with vital, actionable information for effectively managing Multiple Myeloma, a serious blood cancer. Additionally, Telo Genomics offers TeloView, a proprietary software system capable of precisely measuring individual patient telomere characteristics. Telo Genomics caters to a broad spectrum of clients, including diagnostic pathologists, clinical doctors, academic researchers, and pharmaceutical developers. A notable endorsement of its technology is a collaborative agreement with the renowned Mayo Clinic, aimed at validating the Telo-MM diagnostic tests for multiple myeloma. Founded in 2014 and based in Toronto, Canada, the company adopted its current name, Telo Genomics Corp., in April 2019, having previously operated as 3D Signatures Inc.
- ISIN
- CA87975M2085
- Listed since
- Feb 15, 2012
- Exchange
- TSX Venture Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Nymox Pharmaceutical CorporationOTCPK: NYMX.F | $4.41M | $0.04 | +31.25% |
| Azitra, Inc.NYSEAM: AZTR | $4.33M | $0.07 | -44.96% |
| Kane Biotech Inc.TSXV: KNE | $4.33M | CA$0.03 | -16.67% |
| NuCana plcNasdaqCM: NCNA | $4.27M | $0.99 | -9.99% |
| Strategic Partners A/SCPSE: STRAP | $4.11M | Dkr655.00 | -2.96% |
| Medicus Pharma Ltd.NasdaqCM: MDCX | $4.11M | $3.25 | 0.00% |
| Liminatus Pharma, Inc.NasdaqCM: LIMN | $4.08M | $3.04 | -19.15% |
| Enlivex Ltd.NasdaqCM: ENLV | $4.08M | $0.21 | -19.29% |
Figures last refreshed Oct 18, 2026.